Benjamin Click
Concepts (234)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Crohn Disease | 40 | 2025 | 243 | 14.220 |
Why?
| | Inflammatory Bowel Diseases | 32 | 2025 | 351 | 8.700 |
Why?
| | Colitis, Ulcerative | 14 | 2025 | 136 | 3.570 |
Why?
| | Ileum | 13 | 2025 | 119 | 3.160 |
Why?
| | Recurrence | 17 | 2025 | 1060 | 3.080 |
Why?
| | Colonoscopy | 10 | 2025 | 245 | 2.880 |
Why?
| | Biological Products | 9 | 2023 | 216 | 2.430 |
Why?
| | Ustekinumab | 8 | 2024 | 15 | 1.960 |
Why?
| | Gastrointestinal Agents | 6 | 2024 | 65 | 1.770 |
Why?
| | Colon | 9 | 2025 | 282 | 1.560 |
Why?
| | Ileostomy | 4 | 2025 | 20 | 1.370 |
Why?
| | Patient-Centered Care | 4 | 2024 | 530 | 1.240 |
Why?
| | Postoperative Complications | 9 | 2025 | 2654 | 1.100 |
Why?
| | Mesentery | 2 | 2024 | 48 | 1.060 |
Why?
| | Secondary Prevention | 2 | 2025 | 233 | 1.060 |
Why?
| | Remission Induction | 7 | 2025 | 288 | 0.910 |
Why?
| | Holistic Health | 1 | 2024 | 15 | 0.890 |
Why?
| | Anastomosis, Surgical | 6 | 2025 | 153 | 0.860 |
Why?
| | Health Expenditures | 3 | 2020 | 189 | 0.840 |
Why?
| | Adult | 41 | 2025 | 37929 | 0.830 |
Why?
| | Retrospective Studies | 24 | 2025 | 15657 | 0.820 |
Why?
| | Humans | 70 | 2025 | 137585 | 0.770 |
Why?
| | Delivery of Health Care | 2 | 2020 | 951 | 0.770 |
Why?
| | Tumor Necrosis Factor-alpha | 5 | 2021 | 1242 | 0.760 |
Why?
| | Health Care Costs | 3 | 2020 | 398 | 0.760 |
Why?
| | Diverticulitis | 1 | 2022 | 8 | 0.750 |
Why?
| | Hypoalbuminemia | 1 | 2021 | 30 | 0.720 |
Why?
| | Dermatologic Agents | 1 | 2021 | 70 | 0.680 |
Why?
| | Cost of Illness | 2 | 2020 | 308 | 0.660 |
Why?
| | Risk Factors | 14 | 2025 | 10388 | 0.650 |
Why?
| | C-Reactive Protein | 4 | 2016 | 410 | 0.650 |
Why?
| | Proctocolectomy, Restorative | 4 | 2024 | 20 | 0.640 |
Why?
| | Patient Acceptance of Health Care | 4 | 2020 | 806 | 0.620 |
Why?
| | Health Resources | 2 | 2018 | 120 | 0.590 |
Why?
| | Gastric Bypass | 1 | 2020 | 119 | 0.590 |
Why?
| | Colonic Pouches | 3 | 2024 | 15 | 0.590 |
Why?
| | Small Molecule Libraries | 1 | 2019 | 94 | 0.580 |
Why?
| | Demyelinating Diseases | 1 | 2019 | 85 | 0.580 |
Why?
| | Middle Aged | 29 | 2025 | 33479 | 0.560 |
Why?
| | Colitis | 1 | 2020 | 266 | 0.540 |
Why?
| | Bariatric Surgery | 1 | 2020 | 217 | 0.520 |
Why?
| | Antibodies, Monoclonal, Humanized | 4 | 2024 | 804 | 0.510 |
Why?
| | Obesity, Morbid | 1 | 2020 | 264 | 0.500 |
Why?
| | Costs and Cost Analysis | 1 | 2016 | 213 | 0.490 |
Why?
| | Adenoma | 1 | 2018 | 230 | 0.490 |
Why?
| | Colonic Neoplasms | 1 | 2018 | 258 | 0.490 |
Why?
| | Eosinophilia | 1 | 2017 | 218 | 0.470 |
Why?
| | Male | 38 | 2025 | 67762 | 0.470 |
Why?
| | Asymptomatic Diseases | 1 | 2015 | 89 | 0.460 |
Why?
| | Blood Component Removal | 1 | 2015 | 25 | 0.460 |
Why?
| | Hypertriglyceridemia | 1 | 2015 | 39 | 0.460 |
Why?
| | Gastrointestinal Tract | 1 | 2017 | 195 | 0.450 |
Why?
| | Quality Improvement | 2 | 2020 | 1178 | 0.440 |
Why?
| | Constriction, Pathologic | 4 | 2023 | 245 | 0.440 |
Why?
| | Anti-Inflammatory Agents | 2 | 2017 | 496 | 0.430 |
Why?
| | Spondylarthritis | 2 | 2025 | 50 | 0.430 |
Why?
| | Prospective Studies | 14 | 2022 | 7604 | 0.430 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2017 | 261 | 0.430 |
Why?
| | Pancreatitis | 1 | 2015 | 134 | 0.430 |
Why?
| | Female | 37 | 2025 | 73304 | 0.420 |
Why?
| | Severity of Illness Index | 7 | 2018 | 2828 | 0.410 |
Why?
| | Antibodies, Monoclonal | 2 | 2024 | 1430 | 0.400 |
Why?
| | Quality of Life | 10 | 2022 | 2892 | 0.400 |
Why?
| | Sweet Syndrome | 2 | 2023 | 8 | 0.390 |
Why?
| | Treatment Outcome | 9 | 2025 | 10811 | 0.360 |
Why?
| | Mental Disorders | 2 | 2017 | 1077 | 0.360 |
Why?
| | Cecum | 2 | 2023 | 33 | 0.350 |
Why?
| | Hospitalization | 3 | 2020 | 2199 | 0.340 |
Why?
| | Colorectal Neoplasms | 1 | 2018 | 806 | 0.330 |
Why?
| | Disease Progression | 6 | 2022 | 2757 | 0.330 |
Why?
| | Registries | 8 | 2022 | 2035 | 0.320 |
Why?
| | Anemia | 3 | 2016 | 170 | 0.320 |
Why?
| | Dilatation | 2 | 2020 | 67 | 0.320 |
Why?
| | Endoscopy | 2 | 2023 | 318 | 0.310 |
Why?
| | Drug Monitoring | 2 | 2022 | 218 | 0.310 |
Why?
| | Pennsylvania | 6 | 2018 | 116 | 0.310 |
Why?
| | Anus Diseases | 2 | 2020 | 9 | 0.300 |
Why?
| | Telemedicine | 1 | 2018 | 862 | 0.300 |
Why?
| | Aged | 12 | 2023 | 23961 | 0.290 |
Why?
| | Leukocyte L1 Antigen Complex | 2 | 2025 | 32 | 0.290 |
Why?
| | Biological Therapy | 3 | 2022 | 29 | 0.280 |
Why?
| | Young Adult | 10 | 2025 | 13209 | 0.270 |
Why?
| | Cost-Benefit Analysis | 2 | 2020 | 591 | 0.270 |
Why?
| | Pouchitis | 2 | 2024 | 7 | 0.260 |
Why?
| | Predictive Value of Tests | 2 | 2025 | 2031 | 0.260 |
Why?
| | Colectomy | 2 | 2024 | 100 | 0.250 |
Why?
| | Risk | 2 | 2019 | 912 | 0.240 |
Why?
| | Risk Assessment | 4 | 2025 | 3457 | 0.240 |
Why?
| | Biopsy | 3 | 2024 | 1129 | 0.240 |
Why?
| | Necrosis | 2 | 2023 | 246 | 0.240 |
Why?
| | Brain | 1 | 2017 | 2668 | 0.230 |
Why?
| | Biomarkers | 4 | 2025 | 4149 | 0.210 |
Why?
| | Neoplasms | 1 | 2019 | 2671 | 0.210 |
Why?
| | Social Isolation | 1 | 2023 | 62 | 0.200 |
Why?
| | Comparative Effectiveness Research | 2 | 2021 | 152 | 0.200 |
Why?
| | Reoperation | 2 | 2022 | 573 | 0.190 |
Why?
| | Intestinal Mucosa | 2 | 2024 | 623 | 0.180 |
Why?
| | Time Factors | 6 | 2025 | 6828 | 0.180 |
Why?
| | Propensity Score | 2 | 2020 | 294 | 0.180 |
Why?
| | Anus Neoplasms | 1 | 2021 | 33 | 0.180 |
Why?
| | Adenomatous Polyposis Coli | 1 | 2021 | 39 | 0.170 |
Why?
| | Skin Neoplasms | 2 | 2019 | 855 | 0.170 |
Why?
| | Economics, Medical | 1 | 2020 | 6 | 0.170 |
Why?
| | Rheumatic Diseases | 1 | 2021 | 81 | 0.170 |
Why?
| | Radiation Injuries | 1 | 2021 | 145 | 0.170 |
Why?
| | Chemoradiotherapy | 1 | 2021 | 225 | 0.160 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2022 | 228 | 0.160 |
Why?
| | Fibrosis | 2 | 2020 | 552 | 0.160 |
Why?
| | Pulmonary Embolism | 1 | 2022 | 226 | 0.160 |
Why?
| | Electronic Health Records | 2 | 2018 | 1069 | 0.160 |
Why?
| | Infliximab | 1 | 2020 | 111 | 0.160 |
Why?
| | Intestinal Obstruction | 1 | 2020 | 51 | 0.160 |
Why?
| | Gastrectomy | 1 | 2020 | 126 | 0.150 |
Why?
| | Analgesics, Opioid | 2 | 2018 | 1000 | 0.150 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2022 | 279 | 0.150 |
Why?
| | Adolescent | 6 | 2022 | 21513 | 0.150 |
Why?
| | Drug Substitution | 1 | 2019 | 54 | 0.150 |
Why?
| | Combined Modality Therapy | 1 | 2022 | 1236 | 0.150 |
Why?
| | Cross-Sectional Studies | 3 | 2025 | 5472 | 0.150 |
Why?
| | Sigmoidoscopy | 1 | 2018 | 12 | 0.150 |
Why?
| | Deprescriptions | 1 | 2019 | 35 | 0.150 |
Why?
| | Multivariate Analysis | 3 | 2018 | 1509 | 0.140 |
Why?
| | Health Services Misuse | 1 | 2018 | 33 | 0.140 |
Why?
| | Linear Models | 1 | 2020 | 849 | 0.140 |
Why?
| | Venous Thromboembolism | 1 | 2022 | 316 | 0.140 |
Why?
| | Surveys and Questionnaires | 6 | 2025 | 5778 | 0.140 |
Why?
| | Pyrroles | 1 | 2019 | 213 | 0.140 |
Why?
| | Lymphoma | 1 | 2019 | 208 | 0.140 |
Why?
| | Piperidines | 1 | 2019 | 206 | 0.130 |
Why?
| | Disease Management | 2 | 2020 | 628 | 0.130 |
Why?
| | Cohort Studies | 4 | 2025 | 5742 | 0.130 |
Why?
| | Thyroid Neoplasms | 1 | 2021 | 343 | 0.130 |
Why?
| | Clostridium Infections | 1 | 2017 | 73 | 0.130 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2023 | 1079 | 0.130 |
Why?
| | Skin Diseases | 1 | 2018 | 149 | 0.130 |
Why?
| | Models, Organizational | 1 | 2017 | 151 | 0.130 |
Why?
| | Unemployment | 1 | 2016 | 43 | 0.130 |
Why?
| | Drug Prescriptions | 1 | 2018 | 245 | 0.120 |
Why?
| | Dermatology | 1 | 2018 | 127 | 0.120 |
Why?
| | Follow-Up Studies | 4 | 2018 | 5131 | 0.120 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2021 | 683 | 0.120 |
Why?
| | Intestines | 1 | 2019 | 357 | 0.120 |
Why?
| | United States | 6 | 2025 | 14841 | 0.120 |
Why?
| | Adalimumab | 1 | 2015 | 48 | 0.120 |
Why?
| | Case-Control Studies | 2 | 2020 | 3556 | 0.120 |
Why?
| | Pyrimidines | 1 | 2019 | 470 | 0.120 |
Why?
| | Weight Loss | 1 | 2020 | 787 | 0.110 |
Why?
| | Incidence | 2 | 2018 | 2804 | 0.110 |
Why?
| | Inflammation | 2 | 2024 | 2837 | 0.110 |
Why?
| | Kaplan-Meier Estimate | 1 | 2015 | 889 | 0.100 |
Why?
| | Hemoglobins | 1 | 2015 | 353 | 0.100 |
Why?
| | Protein Kinase Inhibitors | 1 | 2019 | 916 | 0.100 |
Why?
| | Patient Care Team | 1 | 2017 | 631 | 0.090 |
Why?
| | Melanoma | 1 | 2019 | 760 | 0.090 |
Why?
| | Longitudinal Studies | 4 | 2025 | 2844 | 0.090 |
Why?
| | Prognosis | 1 | 2020 | 4030 | 0.090 |
Why?
| | Arthritis, Rheumatoid | 1 | 2020 | 1167 | 0.090 |
Why?
| | Comorbidity | 1 | 2016 | 1622 | 0.090 |
Why?
| | Needs Assessment | 2 | 2022 | 376 | 0.070 |
Why?
| | Logistic Models | 3 | 2018 | 2074 | 0.070 |
Why?
| | Diabetes Mellitus | 1 | 2016 | 1040 | 0.070 |
Why?
| | Hypertension | 1 | 2016 | 1295 | 0.070 |
Why?
| | Immunologic Factors | 2 | 2021 | 236 | 0.070 |
Why?
| | Iron Compounds | 2 | 2016 | 6 | 0.060 |
Why?
| | Blood Sedimentation | 2 | 2016 | 39 | 0.060 |
Why?
| | Age Factors | 2 | 2025 | 3295 | 0.060 |
Why?
| | Prevalence | 2 | 2025 | 2734 | 0.050 |
Why?
| | United States Food and Drug Administration | 1 | 2024 | 208 | 0.050 |
Why?
| | Aged, 80 and over | 3 | 2022 | 7635 | 0.050 |
Why?
| | Mitomycin | 1 | 2021 | 34 | 0.050 |
Why?
| | Resilience, Psychological | 1 | 2023 | 128 | 0.050 |
Why?
| | Proportional Hazards Models | 1 | 2025 | 1266 | 0.050 |
Why?
| | Sutures | 1 | 2022 | 58 | 0.050 |
Why?
| | Fistula | 1 | 2022 | 47 | 0.040 |
Why?
| | Operative Time | 1 | 2022 | 145 | 0.040 |
Why?
| | Fluorouracil | 1 | 2021 | 208 | 0.040 |
Why?
| | Feces | 1 | 2023 | 484 | 0.040 |
Why?
| | Aftercare | 1 | 2022 | 208 | 0.040 |
Why?
| | Safety | 1 | 2022 | 338 | 0.040 |
Why?
| | Liver Cirrhosis | 1 | 2022 | 316 | 0.040 |
Why?
| | Guideline Adherence | 1 | 2023 | 556 | 0.040 |
Why?
| | Sex Factors | 1 | 2025 | 2071 | 0.040 |
Why?
| | Tomography, X-Ray Computed | 2 | 2020 | 2691 | 0.040 |
Why?
| | Phenotype | 2 | 2017 | 3196 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2022 | 956 | 0.030 |
Why?
| | Patient Preference | 1 | 2020 | 191 | 0.030 |
Why?
| | Laparoscopy | 1 | 2022 | 466 | 0.030 |
Why?
| | Anticoagulants | 1 | 2022 | 664 | 0.030 |
Why?
| | Smoking | 1 | 2025 | 1627 | 0.030 |
Why?
| | Hospitals | 1 | 2022 | 691 | 0.030 |
Why?
| | Survival Rate | 1 | 2021 | 1972 | 0.030 |
Why?
| | Animals | 1 | 2019 | 36940 | 0.030 |
Why?
| | Qualitative Research | 1 | 2023 | 1386 | 0.030 |
Why?
| | Anxiety | 1 | 2023 | 1035 | 0.030 |
Why?
| | Patient Reported Outcome Measures | 1 | 2020 | 402 | 0.030 |
Why?
| | Pain Measurement | 1 | 2018 | 521 | 0.030 |
Why?
| | Vitamin D Deficiency | 1 | 2017 | 186 | 0.030 |
Why?
| | Bacillus subtilis | 2 | 1972 | 66 | 0.030 |
Why?
| | Depression | 1 | 2023 | 1397 | 0.030 |
Why?
| | Ambulatory Care | 1 | 2018 | 546 | 0.030 |
Why?
| | Bacteriophages | 2 | 1972 | 98 | 0.030 |
Why?
| | Liver | 1 | 2022 | 1943 | 0.030 |
Why?
| | Early Detection of Cancer | 1 | 2018 | 447 | 0.030 |
Why?
| | DNA, Viral | 2 | 1972 | 364 | 0.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 1692 | 0.020 |
Why?
| | Lysogeny | 1 | 1971 | 5 | 0.020 |
Why?
| | Academic Medical Centers | 1 | 2015 | 512 | 0.020 |
Why?
| | Biomedical Research | 1 | 2016 | 692 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2020 | 3566 | 0.020 |
Why?
| | Anti-Bacterial Agents | 1 | 2017 | 1809 | 0.020 |
Why?
| | Emergency Service, Hospital | 1 | 2018 | 2069 | 0.020 |
Why?
| | Mutation | 2 | 1972 | 3958 | 0.010 |
Why?
| | DNA Replication | 2 | 1972 | 238 | 0.010 |
Why?
| | Centrifugation, Density Gradient | 2 | 1972 | 41 | 0.010 |
Why?
| | Tritium | 2 | 1972 | 76 | 0.010 |
Why?
| | Uridine | 2 | 1972 | 30 | 0.010 |
Why?
| | Mitomycins | 1 | 1972 | 4 | 0.010 |
Why?
| | Nitrosoguanidines | 1 | 1971 | 1 | 0.010 |
Why?
| | Cesium | 1 | 1971 | 20 | 0.010 |
Why?
| | Temperature | 2 | 1972 | 679 | 0.010 |
Why?
| | Cell-Free System | 1 | 1971 | 53 | 0.010 |
Why?
| | Mutagens | 1 | 1971 | 22 | 0.010 |
Why?
| | Spectrophotometry | 1 | 1971 | 61 | 0.010 |
Why?
| | Oxides | 1 | 1971 | 46 | 0.010 |
Why?
| | Muramidase | 1 | 1971 | 78 | 0.010 |
Why?
| | Culture Media | 1 | 1971 | 165 | 0.010 |
Why?
| | Deuterium | 1 | 1971 | 99 | 0.010 |
Why?
| | Chlorides | 1 | 1971 | 136 | 0.010 |
Why?
| | DNA, Bacterial | 1 | 1971 | 337 | 0.010 |
Why?
| | Viral Proteins | 1 | 1972 | 342 | 0.010 |
Why?
| | Bacteriolysis | 1 | 1972 | 9 | 0.000 |
Why?
| | Transferases | 1 | 1972 | 33 | 0.000 |
Why?
| | Adenine | 1 | 1972 | 271 | 0.000 |
Why?
| | Virus Replication | 1 | 1972 | 483 | 0.000 |
Why?
|
|
Click's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|